

Detailed description of the subject of the order

Purchase financed from the state budget from the Medical Research Agency as part of the project:

Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety

Financing contract number: 2021/ABM/05/00004-00

Technical specification:

- I. 5 antisense oligonucleotides (ASO) 300 nmol each, have to be able to block polyadenylation sites. Hence, they need to operate via an RNase H-independent steric blocking mechanism. It is necessary that required ASOs are comprised of a nucleic acid base, a methylenemorpholine ring and a non-ionic phosphorodiamidate intersubunit linkage. Sequences of oligonucleotides that are the subject of the order:
 1. Custom Oligo 1 – ACTTTATTTACTATTTATTGCACAT
 2. Custom Oligo 2 – ACTATTTTATTATGGCACACAGGAT
 3. Custom Oligo 3 - TCCTGGAATTTTCCTTCTTATTAT
 4. Custom Oligo 4 – AGGCTACCCTTTAATGTGTCTCATT
 5. Custom Oligo 5 - ACGTTTTATTTTAATTCTCACCATT
- II. Control oligo (ASO), 300 nmol. It is necessary that required ASO is comprised of a nucleic acid base, a methylenemorpholine ring and a non-ionic phosphorodiamidate intersubunit linkage. It is essential for the control oligo to have a conjugated fluorescent tag on its 3' end.
- III. Chemical reagent which allows the delivery of ASOs into eukaryotic cells (volume: 1 ml).